Journals / art / 2014 / Cilt: 29 - Sayı: 1

Disease activity and related variables in patients with psoriatic arthritis

Journal
art
Pages
8–13
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, the DAS28 is a helpful adjunctive measurement instrument for assessing PsA activity, and the BASDAI may prove to be more valuable for patients with spondylitis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to investigate the disease activity and related variables in patients with psoriatic arthritis (PsA).
📊
Key Findings & Data:The disease was assessed using the Disease Activity Score for Reactive Arthritis (DAREA) index, the Disease Activity Score including 28 joints (DAS28), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Psoriasis Area and Severity Index (PASI).
💡
Conclusion & Impact:Furthermore, the DAS28 is a helpful adjunctive measurement instrument for assessing PsA activity, and the BASDAI may prove to be more valuable for patients with spondylitis.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to investigate the disease activity and related variables in patients with psoriatic arthritis (PsA). Patients and methods: Fifty patients with PsA, who were diagnosed based on the Classification Criteria for Psoriatic Arthritis (CASPAR), were included. The patients were divided into five groups according to the Moll and Wright criteria. The disease was assessed using the Disease Activity Score for Reactive Arthritis (DAREA) index, the Disease Activity Score including 28 joints (DAS28), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Psoriasis Area and Severity Index (PASI). In the laboratory tests, the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels were determined, and a functional assessment was performed using the Health Assessment Questionnaire (HAQ). Pain was evaluated via the Visual Analog Scale for Pain (VAS-Pain), and the Patient Global Assessment (PaGA) and Physician Global Assessment (PhGA) results were recorded. Results: The asymmetrical oligoarticular type of PsA was seen most often (n=28, 56%), with the distal interphalangeal predominant type of PsA (n=2, 4%) and arthritis mutilans (n=2) being the least frequent. There were statistically significant correlations between the DAREA score and the CRP and ESR levels as well as the VAS, PaGA, DAS28, and HAQ scores. The BASDAI scores had statistically significant relationships with the PaGA and PhGA in the group with spondylitis. Conclusion: We determined that the DAREA, as a disease activity index, was well correlated with both the laboratory and clinical assessment findings in patients with PsA. Furthermore, the DAS28 is a helpful adjunctive measurement instrument for assessing PsA activity, and the BASDAI may prove to be more valuable for patients with spondylitis.

🔖

Cite This Article

YURDAKUL, F. G., ESER, F., BODUR, H., GÜL, Ü., GÖNÜL, M., OĞUZ, I. D. (2014). Disease activity and related variables in patients with psoriatic arthritis. art, Cilt: 29 - Sayı: 1, 8–13. https://ajindex.com/articles/200485

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Gladman DD, Clinical Features of Psoriatic Arthritis. In: Ricthlin CT, FitzGerald O, editors. 1st ed. Philedephia: Mosby, Inc affiliate of Elsevier Inc.; 2007. p. 11–19
  2. Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973;32:181–201
  3. Goupille P. Psoriatic arthritis. Joint Bone Spine 2005;72:466–70
  4. Bruce IN, Psoriatic arthritis: clinical features. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. 4th ed. Philedephia: Mosby, Inc affiliate of Elsevier Inc. 2008. p. 1165–77
  5. Turkiewicz AM, Moreland LW. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum 2007;56:1051–66
  6. Fredriksson T, Pettersson U. Severe psoriasis- -oral therapy with a new retinoid. Dermatologica 1978;157:238–44
  7. Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen JS. Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology (Oxford) 2000;39:148–55
  8. Taylor WJ, Harrison AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 2004;51:311–5
  9. Küçükdeveci AA, Sahin H, Ataman S, Griffiths B, Tennant A. Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum 2004;51:14–9
  10. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009;61:1373–8
  11. Green L, Meyers OL, Gordon W, Briggs B. Arthritis in psoriasis. Ann Rheum Dis 1981;40:366–9
  12. Moghaddassi M, Shahram F, Chams-Davatchi C, Najafizadeh SR, Davatchi F. Different aspects of psoriasis: analysis of 150 Iranian patients. Arch Iran Med 2009;12:279–83
  13. Kammer GM, Soter NA, Gibson DJ, Schur PH. Psoriatic arthritis: a clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum 1979;9:75–97
  14. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med 1987;62:127–41
  15. Jamshidi F, Bouzari N, Seirafi H, Farnaghi F, Firooz A. The prevalence of PsA in Ps patients in Tehran, Iran. Arch Iranian Med 2008;11:162–5
  16. Gladman DD. Psoriatic arthritis. Dermatologic Therapy 2004;17:350–63
  17. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA s